ReviewFrontiers in medicine2022
Positron emission tomography imaging of lung cancer: An overview of alternative positron emission tomography tracers beyond F18 fluorodeoxyglucose.
Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- [Frontiers in medicine · 2024Pooled it
- Specific PET Imaging for Precision Management of Lung Cancer: Advances, Clinical Translation and Future Directions.Chemical & biomedical imaging · 2026Review
- Predicting PD-L1 expression status in NSCLC using radiomic analysis of 18 F-FDG-PET/CT images.European journal of nuclear medicine and molecular imaging · 2026Article
- Paving the way for future PSMA inhibitors: insights from comparative preclinical evaluations of structure modifications.EJNMMI radiopharmacy and chemistry · 2025Article
- Flexible Bronchoscopy and Non-Small-Cell Lung Cancer Staging: A Narrative Review of Modern Techniques for Optimized Clinical Decision-Making.Journal of clinical medicine · 2025Review
- Absent preoperative non-small cell lung cancer confirmation and relevant stage migration in the era before neoadjuvant chemoimmunotherapy: implications for treatment decisions in resectable non-small cell lung cancer.Translational lung cancer research · 2025Article
- Advancements in Cancer Care by Exploring Multimodality Imaging Techniques and their Applications.Current medical imaging · 2025Review
- Article
- Lung imaging methods: indications, strengths and limitations.Breathe (Sheffield, England) · 2024Review
- Article
- Editorial: Reviews in: nuclear medicine 2023.Frontiers in medicine · 2024Article
- Immunotherapy and Chemotherapy Versus Sleep Disturbances for NSCLC Patients.Current oncology (Toronto, Ont.) · 2023Article
- Synthesis, radiolabeling, and evaluation of 68Ga-labeled aminoquinoxaline derivative as a potent PFKFB3-targeted PET tracer.Frontiers in chemistry · 2023Article
- The impact of radiometabolic features on the stage and survival in small cell lung cancer.Annals of thoracic medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer has been the leading cause of cancer-related mortality in China in recent decades. Positron emission tomography-computer tomography (PET/CT) has been established in the diagnosis of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.